03:16 PM EDT, 06/07/2024 (MT Newswires) -- Arcturus Therapeutics ( ARCT ) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis.

Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled therapeutic generally was safe and well tolerated among the healthy patients participating in the early-stage trial as well as the four adult patients with cystic fibrosis.

Lung function also improved in the cystic fibrosis patients after they received two doses of ARCT-032, the company said. It plans to complete phase 1b shortly.

Price: 30.10, Change: -12.50, Percent Change: -29.34